Investors

News & Publications

News Releases

News Releases

May 8, 2019
Arvinas Reports First Quarter Financial Results and Provides Corporate Update
Initiated Patient Dosing in the First Phase 1 Clinical Trial with a Targeted PROTAC® Protein Degrader, ARV-110 NEW HAVEN, Conn. , May 08, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biopharmaceutical company creating a new class of therapies that degrades disease-causing proteins,
Displaying 11 - 19 of 19